-
1
-
-
33847172367
-
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
-
Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
-
(2007)
N Engl J Med
, vol.356
, pp. 775-789
-
-
Calverley, P.M.1
Anderson, J.A.2
Celli, B.3
-
2
-
-
48949103222
-
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study
-
Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
-
(2008)
Am J Respir Crit Care Med
, vol.178
, pp. 332-338
-
-
Celli, B.R.1
Thomas, N.E.2
Anderson, J.A.3
-
3
-
-
53749102775
-
A 4-year trial of tiotropium in chronic obstructive pulmonary disease
-
Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
-
(2008)
N Engl J Med
, vol.359
, pp. 1543-1554
-
-
Tashkin, D.P.1
Celli, B.2
Senn, S.3
-
4
-
-
79953083992
-
BPCO et inflammation: Mise au point d'un group d'experts. Les mécanismes de l'inflammation et du remodelage
-
Aubier M, Marthan R, Berger P, et al. BPCO et inflammation: mise au point d'un group d'experts. Les mécanismes de l'inflammation et du remodelage [COPD and inflammation: statement from a French expert group: inflammation and remodelling mechanisms]. Rev Mal Respir 2010; 27: 1254-1266.
-
(2010)
Rev Mal Respir
, vol.27
, pp. 1254-1266
-
-
Aubier, M.1
Marthan, R.2
Berger, P.3
-
5
-
-
85017458214
-
BPCO et inflammation: Mise au point d'un group d'experts. Les phénotypes en lien avec l'inflammation
-
Pérez T, Mal H, Aguilaniu B, et al. BPCO et inflammation: mise au point d'un group d'experts. Les phénotypes en lien avec l'inflammation [COPD and inflammation: statement from a French expert group. Phenotypes related to inflammation]. Rev Mal Respir 2011; 28: 192-215.
-
(2011)
Rev Mal Respir
, vol.28
, pp. 192-215
-
-
Pérez, T.1
Mal, H.2
Aguilaniu, B.3
-
6
-
-
79959551393
-
BPCO et inflammation: Mise au point d'un group d'experts. Comment traiter l'inflammation?
-
Roche N, Devillier P, Aguilaniu B, et al. BPCO et inflammation: mise au point d'un group d'experts. Comment traiter l'inflammation? [COPD and inflammation: statement from a French expert group. How to treat inflammation?]. Rev Mal Respir 2011; 28: 427-442.
-
(2011)
Rev Mal Respir
, vol.28
, pp. 427-442
-
-
Roche, N.1
Devillier, P.2
Aguilaniu, B.3
-
7
-
-
0027410275
-
Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis
-
Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147: 301-306.
-
(1993)
Am Rev Respir Dis
, vol.147
, pp. 301-306
-
-
Saetta, M.1
di Stefano, A.2
Maestrelli, P.3
-
8
-
-
2942720573
-
The nature of small-airway obstruction in chronic obstructive pulmonary disease
-
Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
-
(2004)
N Engl J Med
, vol.350
, pp. 2645-2653
-
-
Hogg, J.C.1
Chu, F.2
Utokaparch, S.3
-
9
-
-
66649127821
-
Immunologic aspects of chronic obstructive pulmonary disease
-
Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 2445-2454.
-
(2009)
N Engl J Med
, vol.360
, pp. 2445-2454
-
-
Cosio, M.G.1
Saetta, M.2
Agusti, A.3
-
10
-
-
72549087224
-
Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease
-
Freeman CM, Martinez FJ, Han MK, et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 1179-1188.
-
(2009)
Am J Respir Crit Care Med
, vol.180
, pp. 1179-1188
-
-
Freeman, C.M.1
Martinez, F.J.2
Han, M.K.3
-
11
-
-
69249128696
-
Lymphoid follicles in (very) severe COPD: Beneficial or harmful?
-
Brusselle GG, Demoor T, Bracke KR, et al. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J 2009; 34: 219-230.
-
(2009)
Eur Respir J
, vol.34
, pp. 219-230
-
-
Brusselle, G.G.1
Demoor, T.2
Bracke, K.R.3
-
13
-
-
57349099228
-
Emerging Pharmacotherapies for COPD
-
Barnes PJ. Emerging Pharmacotherapies for COPD. Chest 2008; 134: 1278-1286.
-
(2008)
Chest
, vol.134
, pp. 1278-1286
-
-
Barnes, P.J.1
-
14
-
-
17644373481
-
Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease
-
MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 50-60.
-
(2005)
Proc Am Thorac Soc
, vol.2
, pp. 50-60
-
-
Macnee, W.1
-
15
-
-
32644486046
-
Aerobic capacity, oxidant stress, and chronic obstructive pulmonary disease - a new take on an old hypothesis
-
Stevenson CS, Koch LG, Britton SL. Aerobic capacity, oxidant stress, and chronic obstructive pulmonary disease - a new take on an old hypothesis. Pharmacol Ther 2006; 110: 71-82.
-
(2006)
Pharmacol Ther
, vol.110
, pp. 71-82
-
-
Stevenson, C.S.1
Koch, L.G.2
Britton, S.L.3
-
16
-
-
58249099942
-
COPD as a disease of accelerated lung aging
-
Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-180.
-
(2009)
Chest
, vol.135
, pp. 173-180
-
-
Ito, K.1
Barnes, P.J.2
-
17
-
-
65849427529
-
Glucocorticoid resistance in inflammatory diseases
-
Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373: 1905-17.
-
(2009)
Lancet
, vol.373
, pp. 1905-1917
-
-
Barnes, P.J.1
Adcock, I.M.2
-
18
-
-
27144526596
-
Airway and systemic inflammation and decline in lung function in patients with COPD
-
Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995-2004.
-
(2005)
Chest
, vol.128
, pp. 1995-2004
-
-
Donaldson, G.C.1
Seemungal, T.A.2
Patel, I.S.3
-
19
-
-
77956689733
-
Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease
-
Hurst JR, Vestbo J, Anzueto A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
-
(2010)
N Engl J Med
, vol.363
, pp. 1128-1138
-
-
Hurst, J.R.1
Vestbo, J.2
Anzueto, A.3
-
20
-
-
0030061718
-
Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa
-
Di Stefano A, Turato G, Maestrelli P, et al. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med 1996; 153: 629-632.
-
(1996)
Am J Respir Crit Care Med
, vol.153
, pp. 629-632
-
-
di Stefano, A.1
Turato, G.2
Maestrelli, P.3
-
21
-
-
0030900606
-
Inflammation in bronchial biopsies of subjects with chronic bronchitis: Inverse relationship of CD8 T lymphocytes with FEV1
-
O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8 T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857.
-
(1997)
Am J Respir Crit Care Med
, vol.155
, pp. 852-857
-
-
O'Shaughnessy, T.C.1
Ansari, T.W.2
Barnes, N.C.3
-
22
-
-
0035421665
-
Amplification of inflammation in emphysema and its association with latent adenoviral infection
-
Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: 469-473.
-
(2001)
Am J Respir Crit Care Med
, vol.164
, pp. 469-473
-
-
Retamales, I.1
Elliott, W.M.2
Meshi, B.3
-
23
-
-
0033825960
-
Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function
-
Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 2000; 162: 1102-1108.
-
(2000)
Am J Respir Crit Care Med
, vol.162
, pp. 1102-1108
-
-
Nakano, Y.1
Muro, S.2
Sakai, H.3
-
24
-
-
6344267160
-
Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD
-
O'Donnell RA, Peebles C, Ward JA, et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004; 59: 837-842.
-
(2004)
Thorax
, vol.59
, pp. 837-842
-
-
O'Donnell, R.A.1
Peebles, C.2
Ward, J.A.3
-
25
-
-
0036644755
-
Airway inflammation in severe chronic obstructive pulmonary disease: Relationship with lung function and radiologic emphysema
-
Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166: 105-110.
-
(2002)
Am J Respir Crit Care Med
, vol.166
, pp. 105-110
-
-
Turato, G.1
Zuin, R.2
Miniati, M.3
-
26
-
-
0036727140
-
Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations
-
Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-764.
-
(2002)
Thorax
, vol.57
, pp. 759-764
-
-
Patel, I.S.1
Seemungal, T.A.2
Wilks, M.3
-
27
-
-
0034018102
-
Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations
-
Bhowmik A, Seemungal TAR, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-120.
-
(2000)
Thorax
, vol.55
, pp. 114-120
-
-
Bhowmik, A.1
Seemungal, T.A.R.2
Sapsford, R.J.3
-
28
-
-
0035509117
-
Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease
-
Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618-1623.
-
(2001)
Am J Respir Crit Care Med
, vol.164
, pp. 1618-1623
-
-
Seemungal, T.1
Harper-Owen, R.2
Bhowmik, A.3
-
29
-
-
58249088128
-
Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease
-
Baghai-Ravary R, Quint JK, Goldring JJ, et al. Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med 2009; 103: 216-223.
-
(2009)
Respir Med
, vol.103
, pp. 216-223
-
-
Baghai-Ravary, R.1
Quint, J.K.2
Goldring, J.J.3
-
30
-
-
12244264853
-
Systemic effects of chronic obstructive pulmonary disease
-
Agustý́ AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-360.
-
(2003)
Eur Respir J
, vol.21
, pp. 347-360
-
-
Agustý́, A.G.1
Noguera, A.2
Sauleda, J.3
-
31
-
-
33644620786
-
Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells
-
Growcott EJ, Spink KG, Ren X, et al. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res 2006; 7: 9.
-
(2006)
Respir Res
, vol.7
, pp. 9
-
-
Growcott, E.J.1
Spink, K.G.2
Ren, X.3
-
32
-
-
67649873075
-
Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotalineinduced pulmonary hypertension in rats
-
Izikki M, Raffestin B, Klar J, et al. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotalineinduced pulmonary hypertension in rats. J Pharmacol Exp Ther 2009; 330: 54-62.
-
(2009)
J Pharmacol Exp Ther
, vol.330
, pp. 54-62
-
-
Izikki, M.1
Raffestin, B.2
Klar, J.3
-
33
-
-
0030976501
-
Corticosteroid reversibility in COPD is related to features of asthma
-
Chanez P, Vignola AM, O'Shaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155: 1529-1534.
-
(1997)
Am J Respir Crit Care Med
, vol.155
, pp. 1529-1534
-
-
Chanez, P.1
Vignola, A.M.2
O'Shaugnessy, T.3
-
34
-
-
0031045482
-
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
-
Keatings V, Jatakanon A, Worsdell Y, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 548.
-
(1997)
Am J Respir Crit Care Med
, vol.155
, pp. 548
-
-
Keatings, V.1
Jatakanon, A.2
Worsdell, Y.3
-
35
-
-
0031841422
-
Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease
-
Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 583-585.
-
(1998)
Thorax
, vol.53
, pp. 583-585
-
-
Confalonieri, M.1
Mainardi, E.2
della Porta, R.3
-
36
-
-
33645304010
-
Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease
-
Barnes NC, Qiu YS, Pavord ID, et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736-743.
-
(2006)
Am J Respir Crit Care Med
, vol.173
, pp. 736-743
-
-
Barnes, N.C.1
Qiu, Y.S.2
Pavord, I.D.3
-
37
-
-
0036153433
-
Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids
-
Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191.
-
(2002)
Eur Respir J
, vol.19
, pp. 182-191
-
-
Barnes, P.J.1
-
38
-
-
0037246566
-
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
-
Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
-
(2003)
Eur Respir J
, vol.21
, pp. 74-81
-
-
Szafranski, W.1
Cukier, A.2
Ramirez, A.3
-
39
-
-
0345188819
-
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease
-
Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.
-
(1999)
N Engl J Med
, vol.340
, pp. 1948-1953
-
-
Pauwels, R.A.1
Lofdahl, C.G.2
Laitinen, L.A.3
-
40
-
-
0034643610
-
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
-
Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
-
(2000)
BMJ
, vol.320
, pp. 1297-1303
-
-
Burge, P.S.1
Calverley, P.M.2
Jones, P.W.3
-
41
-
-
0033614639
-
Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
-
Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823.
-
(1999)
Lancet
, vol.353
, pp. 1819-1823
-
-
Vestbo, J.1
Sorensen, T.2
Lange, P.3
-
42
-
-
77956344161
-
Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD
-
Worth H, Förster K, Eriksson G, et al. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med 2010; 104: 1450-1459.
-
(2010)
Respir Med
, vol.104
, pp. 1450-1459
-
-
Worth, H.1
Förster, K.2
Eriksson, G.3
-
43
-
-
47049130249
-
Methodological issues in therapeutic trials of COPD
-
Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008; 31: 927-933.
-
(2008)
Eur Respir J
, vol.31
, pp. 927-933
-
-
Suissa, S.1
Ernst, P.2
Vandemheen, K.L.3
-
44
-
-
78649735324
-
Airway mucus function and dysfunction
-
Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010; 363: 2233-2247.
-
(2010)
N Engl J Med
, vol.363
, pp. 2233-2247
-
-
Fahy, J.V.1
Dickey, B.F.2
-
45
-
-
84856097024
-
Mucolytics and other therapeutic agents targeting mucociliary clearance
-
ed. Paris, Elsevier Masson SAS, 6-000-P-010
-
Chapron-Fouché J, Burgel PR. Mucolytics and other therapeutic agents targeting mucociliary clearance. In: EMC Pneumologie, ed. Paris, Elsevier Masson SAS, 2009; 6-000-P-010.
-
(2009)
EMC Pneumologie
-
-
Chapron-Fouché, J.1
Burgel, P.R.2
-
46
-
-
77950937105
-
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease
-
Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; 2: CD001287.
-
(2010)
Cochrane Database Syst Rev
, vol.2
-
-
Poole, P.J.1
Black, P.N.2
-
47
-
-
20944433417
-
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial
-
Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-1560.
-
(2005)
Lancet
, vol.365
, pp. 1552-1560
-
-
Decramer, M.1
Rutten-Van, M.M.2
Dekhuijzen, P.N.3
-
48
-
-
34249652351
-
Antielastin autoimmunity in tobacco smoking-induced emphysema
-
Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13: 567-569.
-
(2007)
Nat Med
, vol.13
, pp. 567-569
-
-
Lee, S.H.1
Goswami, S.2
Grudo, A.3
-
49
-
-
67349212939
-
Matrix metalloproteinase 12 silencing: A therapeutic approach to treat pathological lung tissue remodeling?
-
Garbacki N, Di Valentin E, Piette J, et al. Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling? Pulm Pharmacol Ther 2009; 22: 267-278.
-
(2009)
Pulm Pharmacol Ther
, vol.22
, pp. 267-278
-
-
Garbacki, N.1
di Valentin, E.2
Piette, J.3
-
50
-
-
74049134939
-
MMP12, lung function, and COPD in high-risk populations
-
Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009; 361: 2599-2608.
-
(2009)
N Engl J Med
, vol.361
, pp. 2599-2608
-
-
Hunninghake, G.M.1
Cho, M.H.2
Tesfaigzi, Y.3
-
51
-
-
59849113942
-
Attacking the multitiered proteolytic pathology of COPD: New insights from basic and translational studies
-
Djekic UV, Gaggar A, Weathington NM. Attacking the multitiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther 2009; 121: 132-146.
-
(2009)
Pharmacol Ther
, vol.121
, pp. 132-146
-
-
Djekic, U.V.1
Gaggar, A.2
Weathington, N.M.3
-
52
-
-
56749157688
-
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations
-
Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
-
(2008)
Am J Respir Crit Care Med
, vol.178
, pp. 1139-1147
-
-
Seemungal, T.A.1
Wilkinson, T.M.2
Hurst, J.R.3
-
53
-
-
51649104671
-
Advances in neutrophil biology: Clinical implications
-
Cowburn AS, Condliffe AM, Farahi N, et al. Advances in neutrophil biology: clinical implications. Chest 2008; 134: 606-612.
-
(2008)
Chest
, vol.134
, pp. 606-612
-
-
Cowburn, A.S.1
Condliffe, A.M.2
Farahi, N.3
-
54
-
-
53149136171
-
Chemotaxis, chemokine receptors and human disease
-
Jin T, Xu X, Hereld D. Chemotaxis, chemokine receptors and human disease. Cytokine 2008; 44: 1-8.
-
(2008)
Cytokine
, vol.44
, pp. 1-8
-
-
Jin, T.1
Xu, X.2
Hereld, D.3
-
56
-
-
57749100072
-
CXCR2 antagonists for the treatment of pulmonary disease
-
Chapman RW, Phillips JE, Hipkin RW, et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009; 121: 55-68.
-
(2009)
Pharmacol Ther
, vol.121
, pp. 55-68
-
-
Chapman, R.W.1
Phillips, J.E.2
Hipkin, R.W.3
-
57
-
-
33748580720
-
Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease
-
Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006; 27: 546-553.
-
(2006)
Trends Pharmacol Sci
, vol.27
, pp. 546-553
-
-
Donnelly, L.E.1
Barnes, P.J.2
-
58
-
-
33644755474
-
Agents against cytokine synthesis or receptors
-
Yamagata T, Ichinose M. Agents against cytokine synthesis or receptors. Eur J Pharmacol 2006; 533: 289-301.
-
(2006)
Eur J Pharmacol
, vol.533
, pp. 289-301
-
-
Yamagata, T.1
Ichinose, M.2
-
59
-
-
34249045684
-
Emerging trends in the therapy of COPD: Novel anti-inflammatory agents in clinical development
-
Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development. Drug Discov Today 2007; 12: 479-486.
-
(2007)
Drug Discov Today
, vol.12
, pp. 479-486
-
-
Fitzgerald, M.F.1
Fox, J.C.2
-
60
-
-
4544379912
-
Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages
-
Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200: 689-695.
-
(2004)
J Exp Med
, vol.200
, pp. 689-695
-
-
Cosio, B.G.1
Tsaprouni, L.2
Ito, K.3
-
61
-
-
77953310216
-
Treatment effects of lowdose theophylline combined with an inhaled corticosteroid in COPD
-
Ford PA, Durham AL, Russell REK, et al. Treatment effects of lowdose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010; 137: 1338-1344.
-
(2010)
Chest
, vol.137
, pp. 1338-1344
-
-
Ford, P.A.1
Durham, A.L.2
Russell, R.E.K.3
-
62
-
-
36749063803
-
Reduction in sputum neutrophil and eosinophil by the PDE4 inhibitor roflumilast in patients with COPD
-
Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62: 1081-1087.
-
(2007)
Thorax
, vol.62
, pp. 1081-1087
-
-
Grootendorst, D.C.1
Gauw, S.A.2
Verhoosel, R.M.3
-
63
-
-
0142012148
-
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease
-
Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 976-982.
-
(2003)
Am J Respir Crit Care Med
, vol.168
, pp. 976-982
-
-
Gamble, E.1
Grootendorst, D.C.2
Brightling, C.E.3
-
64
-
-
69149103642
-
Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomized clinical trials
-
Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet 2009; 374: 685-694.
-
(2009)
Lancet
, vol.374
, pp. 685-694
-
-
Calverley, P.M.1
Rabe, K.F.2
Goehring, U.M.3
-
65
-
-
69149098943
-
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: Two randomised clinical trials
-
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703.
-
(2009)
Lancet
, vol.374
, pp. 695-703
-
-
Fabbri, L.M.1
Calverley, P.M.2
Izquierdo-Alonso, J.L.3
-
66
-
-
44649152300
-
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases
-
López-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 2008; 8: 286-291.
-
(2008)
Curr Opin Pharmacol
, vol.8
, pp. 286-291
-
-
López-Boado, Y.S.1
Rubin, B.K.2
-
67
-
-
56749157688
-
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations
-
Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
-
(2008)
Am J Respir Crit Care Med
, vol.178
, pp. 1139-1147
-
-
Seemungal, T.A.1
Wilkinson, T.M.2
Hurst, J.R.3
-
68
-
-
80052590900
-
Chronic azithromycin decreases the frequency of chronic obstructive pulmonary disease exacerbations
-
Albert RK, Bailey WC, Casaburi R, et al. Chronic azithromycin decreases the frequency of chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2011; 183: A6416.
-
(2011)
Am J Respir Crit Care Med
, vol.183
-
-
Albert, R.K.1
Bailey, W.C.2
Casaburi, R.3
-
69
-
-
68149180708
-
Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: A review of the evidence
-
Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009; 85: 414-421.
-
(2009)
Postgrad Med J
, vol.85
, pp. 414-421
-
-
Young, R.P.1
Hopkins, R.2
Eaton, T.E.3
-
70
-
-
68349104141
-
Associations between statins and COPD: A systematic review
-
Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009; 9: 32.
-
(2009)
BMC Pulm Med
, vol.9
, pp. 32
-
-
Dobler, C.C.1
Wong, K.K.2
Marks, G.B.3
-
71
-
-
69249112121
-
Statins in COPD. A systematic review
-
Janda S, Park K, Fitzgerald M, et al. Statins in COPD. A systematic review. Chest 2009; 136: 734-743.
-
(2009)
Chest
, vol.136
, pp. 734-743
-
-
Janda, S.1
Park, K.2
Fitzgerald, M.3
-
72
-
-
49349115994
-
Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: Evidence form a retrospective cohort study
-
Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence form a retrospective cohort study. Int J Clin Pract 2008; 62: 1373-1378.
-
(2008)
Int J Clin Pract
, vol.62
, pp. 1373-1378
-
-
Blamoun, A.I.1
Batty, G.N.2
Debari, V.A.3
-
73
-
-
33846931592
-
Statin use is associated with reduced mortality of COPD
-
Soyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality of COPD. Eur Respir J 2007; 29: 279-283.
-
(2007)
Eur Respir J
, vol.29
, pp. 279-283
-
-
Soyseth, V.1
Brekke, P.H.2
Smith, P.3
-
74
-
-
70249144367
-
Impact of statins and ACE inhibitors on mortality after COPD exacerbations
-
Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
-
(2009)
Respir Res
, vol.10
, pp. 45
-
-
Mortensen, E.M.1
Copeland, L.A.2
Pugh, M.J.V.3
-
75
-
-
37549021118
-
The use of statins and lung function in current and former smokers
-
Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007; 132: 1764-1771.
-
(2007)
Chest
, vol.132
, pp. 1764-1771
-
-
Keddissi, J.I.1
Younis, W.G.2
Chbeir, E.A.3
-
76
-
-
35348972883
-
Statin use reduces decline in lung function: VA Normative Aging Study
-
Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176: 742-747.
-
(2007)
Am J Respir Crit Care Med
, vol.176
, pp. 742-747
-
-
Alexeeff, S.E.1
Litonjua, A.A.2
Sparrow, D.3
-
77
-
-
38849125493
-
Usefulnes of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin
-
Lee TM, Lin MS, Chang NC. Usefulnes of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008; 101: 530-535.
-
(2008)
Am J Cardiol
, vol.101
, pp. 530-535
-
-
Lee, T.M.1
Lin, M.S.2
Chang, N.C.3
-
78
-
-
33748701308
-
Regulation of inflammation by PPARs: A future approach to treat lung inflammatory diseases?
-
Becker J, Delayre-Orthez C, Frossard N, et al. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 2006; 20: 429-447.
-
(2006)
Fundam Clin Pharmacol
, vol.20
, pp. 429-447
-
-
Becker, J.1
Delayre-Orthez, C.2
Frossard, N.3
-
79
-
-
33845468172
-
Peroxisome proliferatoractivated receptors-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease
-
Spears M, McSharry C, Thomson NC. Peroxisome proliferatoractivated receptors-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 2006; 36: 1494-1504.
-
(2006)
Clin Exp Allergy
, vol.36
, pp. 1494-1504
-
-
Spears, M.1
McSharry, C.2
Thomson, N.C.3
-
80
-
-
3543104442
-
PPAR-gamma agonists as therapy for diseases involving airway neutrophilia
-
Birrell MA, Patel HJ, McCluskie K, et al. PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur Respir J 2004; 24: 18-23.
-
(2004)
Eur Respir J
, vol.24
, pp. 18-23
-
-
Birrell, M.A.1
Patel, H.J.2
McCluskie, K.3
|